15.11
Modelos Farmacodinâmicos: Modelo Linear de Concentração–Efeito
O modelo linear de concentração–efeito, fundamentado no princípio de que o efeito farmacológico, E, é diretamente proporcional à concentração plasmáti…
O modelo linear concentração-efeito assume que o efeito farmacológico, E, é diretamente proporcional à concentração plasmática do fármaco, C. p.
Ao plotar a concentração plasmática de fármacos em relação a um efeito, a curva concentração-efeito é aproximadamente linear abaixo do EC50.
O modelo postula que o efeito do medicamento aumenta continuamente com o aumento das concentrações até atingir o efeito farmacológico máximo, Emax.
No entanto, essa relação linear não se verifica em uma ampla faixa de concentrações.
Apesar dessas limitações, o modelo é amplamente utilizado para avaliar os efeitos dos medicamentos na repolarização cardíaca, medidos pelo intervalo QT em um eletrocardiograma ou ECG.
Por exemplo, sob esse modelo, o gráfico entre a concentração de moxifloxacina e o prolongamento do intervalo QTc resulta em uma curva linear.
Além disso, a relação concentração-QTc desempenha um papel fundamental na avaliação regulatória da FDA de novos medicamentos para avaliar o risco proarrítmico.
View the full transcript and gain access to JoVE Core videos
Q1: What is the linear concentration-effect model in pharmacodynamics?
The linear concentration-effect model assumes that pharmacological effect (E) is directly proportional to plasma drug concentration (Cp). This model simplifies the Emax model when drug concentrations are significantly below the EC50 threshold. The concentration-effect curve appears approximately linear in this range, with drug effect increasing continuously until reaching maximum pharmacological effect (Emax).
Q2: When is the linear concentration-effect model applicable?
The linear concentration-effect model applies when plasma drug concentrations are markedly below the EC50 threshold, where the relationship between concentration and effect remains approximately linear. However, this linearity does not hold across wide concentration ranges, limiting the model's applicability to comprehensive pharmacodynamic modeling. It is most useful for evaluating specific drug effects within restricted concentration windows.
Q3: How is the linear concentration-effect model used in cardiac safety assessment?
The linear concentration-effect model is widely used to evaluate drug effects on cardiac repolarization, measured by the QT interval on an electrocardiogram (ECG). For example, the plot between moxifloxacin concentration and QTc interval prolongation yields a linear curve. This concentration-QTc relationship plays a key role in the FDA's regulatory evaluation of new drugs for assessing proarrhythmic risk.
Q4: What are the limitations of the linear concentration-effect model?
The linear concentration-effect model assumes continuous effect augmentation with increasing drug concentrations, but this assumption does not hold across extensive concentration ranges. The model's linearity is restricted to conditions where concentrations remain significantly below EC50. These inherent limitations confine its applicability to specific pharmacodynamic scenarios rather than comprehensive drug effect modeling.
Q5: How does the linear model relate to the Emax model?
The linear concentration-effect model emerges as a pivotal simplification of the Emax model for conditions where plasma drug concentration is significantly less than EC50. Under these restricted conditions, the nonlinear Emax relationship approximates a linear trajectory. This simplification allows for straightforward analysis while maintaining accuracy within the applicable concentration range.
Q6: Why is the concentration-QTc relationship important for drug development?
The concentration-QTc relationship facilitates the US FDA's regulatory review processes, particularly in assessing proarrhythmic risks associated with novel therapeutic agents. This analysis has been extensively applied in characterizing moxifloxacin and developing new pharmacological entities. The linear model's utility in this context underscores its significance in advancing drug safety evaluations during regulatory approval.
Q7: What does EC50 represent in the linear concentration-effect model?
EC50 represents the plasma drug concentration at which 50% of the maximum pharmacological effect is achieved. The linear concentration-effect model applies when actual drug concentrations remain significantly below this EC50 threshold. Above EC50, the linear relationship breaks down and the model's assumptions no longer hold, requiring alternative pharmacodynamic models for accurate predictions.